This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Broom, I. Search for Related Content Social Bookmarking                         What's this?

Review: Thinking around abdominal obesity and cardiovascular risk

Robert Gordon University and NHS Grampian, St Andrew Street, Aberdeen, AB25 1HG, Scotland, ext.broom{at}rgu.ac.uk

Obesity, particularly intra-abdominal (visceral) obesity, is a leading cause of cardiovascular disease (CVD), insulin resistance, type 2 diabetes, dyslipidaemia, inflammation and thrombosis. A useful indicator for visceral fat is waist circumference, which is associated with all-cause mortality. Pro-inflammatory adipokines play a causal role in the development of pathologies associated with insulin resistance, type 2 diabetes and CVD. In addition to established anti-obesity therapies, namely orlistat and sibutramine, a new type of agent that inhibits the cannabinoid receptor (CB1) is advanced in development to reduce appetite and act predominantly against intra-abdominal adiposity.

Key Words: abdominal obesity • metabolic syndrome • visceral fat • waist circumference • cardiometabolic risk.

References

• York DA, Rossner S., Caterson I. et al. Obesity, a worldwide epidemic related to heart disease and stroke group I: worldwide demographics of obesity. Circulation 2004;110:e463-70.[Free Full Text]
• Emery EM, Schmid TL, Kahn HS et al. A review of the association between abdominal fat distribution, health outcome measures, and modifiable risk factors. Am J Health Promot 1993;7:342-53.[Medline] [Order article via Infotrieve]
• Despres JP, Lemieux I., Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001;322:716-20.[Free Full Text]
• Eckel RH, Grundy SM, Zimmet PZ The metabolic syndrome. Lancet 2005;365:1415-28.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Stumvoll M., Goldstein BJ, van Haeften TW Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• International Diabetes Federation. The IDF worldwide definition of the metabolic syndrome. Launched 14 April 2005. Accessible via http://www.idf.org/home/index.cfm?unode=32EF2063-B966-468F-928C-A5682A4E3910(accessedSept2005).
• Alberti KG, Zimmet P., Shaw J.; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Reaven GM The metabolic syndrome: requiescat in pace. Clin Chem 2005;51:931-8.[Abstract/Free Full Text]
• Day C. Diagnostic definitions - metabolic syndrome. Br J Diabetes Vasc Dis 2005;5:115-18.[Free Full Text]
• Klein S. The case of visceral fat: argument for the defense. J Clin Invest 2004;113:1530-2.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pouliot MC, Despres JP, Lemieux S. et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bigaard J., Frederiksen K., Tjonneland A. et al. Waist and hip circumferences and all-cause mortality: usefulness of the waist-to-hip ratio? Int J Obes Relat Metab Disord 2004;28:741-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kannel WB, Cupples LA, Ramaswami R. et al. Regional obesity and risk of cardiovascular disease: the Framingham Study. J Clin Epidemiol 1991;44:183-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Yusuf S., Hawken S., Ounpuu S. et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ritchie SA, Ewart MA, Perry CG et al. The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci (Lond) 2004;107:519-32.[Medline] [Order article via Infotrieve]
• Perry C., Sattar N., Petrie J. Adipose tissue: passive sumper active pump. Br J Diabetes Vasc Dis 2001;1:110-14.[Abstract/Free Full Text]
• Lau DC, Dhillon B., Yan H. et al. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 2005;288: H2031-41.[Abstract/Free Full Text]
• Arner P. Insulin resistance in Type 2 diabetes - role of the adipokines. Curr Mol Med 2005;5:333-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wajchenberg BL Subcutaneous and visceral adipose tissue: theirrelation to the metabolic syndrome. Endocr Rev 2000;21:697-738.[Abstract/Free Full Text]
• Fasshauer M., Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003;46:1594-603.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Trayhurn P. The biology of obesity. Proc Nutr Soc 2005;64:31-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hansson GK Inflammation, atherosclerosis, and coronary artery disease. NEJM 2005;352:1685-95.[Free Full Text]
• 3. Stewart KJ, Bacher AC, Turner K. et al. Exercise and risk factors associated with metabolic syndrome in older adults. Am J Prev Med 2005;28:918.
• McAuley KA, Hopkins CM, Smith KJ et al. Comparison of high-fat and high-protein diets with a high-carbohydrate diet in insulin-resistant obese women. Diabetologia 2005;48:8-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pirozzo S., Summerbell C., Cameron C. et al. Advice on low-fat diets for obesity. Cochrane Database Syst Rev 2002;2:CD003640.[Medline] [Order article via Infotrieve]
• Norris SL, Zhang X., Avenell A. et al. Long-term non-pharmacologic weight loss interventions for adults with Type 2 diabetes. Cochrane Database Syst Rev 2005;2:CD004095.[Medline] [Order article via Infotrieve]
• Pagotto U., Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid Type 1 receptors. Lancet 2005;365:1363-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• National Obesity Forum (NOF) Guidelines: Appendix 2 - Accessible via www.nationalobesityforum.org.uk (accessed Sept 2005 ).
• NICE Technology Appraisal Guidance - No. 22: Guidance on the use of orlistat for the treatment of obesity in adults. March 2001.
• NICE Technology Appraisal Guidance - No. 31: Guidance on the use of sibutramine for the treatment of obesity in adults. October 2001.
• Bailey CJ, Day C. New pharmacological approaches to obesity. Obesity in Practice 2005;1:2-5.
• Sjostrom L., Rissanen A., Andersen T. et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Day C., Bailey CJ Sibutramine update. Br J Diabet Vasc Dis 2002;2:392-7.
• James WP, Astrup A., Finer N. et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-25.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Finer N., Pagotto U. The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management. Br J Diabet Vasc Dis 2005;5:121-4.
• Di Marzo V., Goparaju SK, Wang L. et al.Leptin-regulated endocannabi-noids are involved in maintaining food intake. Nature 2001;410:822-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bensaid M., Gary-Bobo M., Esclangon A. et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63:908-14.[Abstract/Free Full Text]
• Rinaldi-Carmona M., Barth F., Heaulme M. et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994;350:240-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ravinet Trillou C., Arnone M., Delgorge C. et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003;284:R345-53.[Abstract/Free Full Text]
• Cota D., Marsicano G., Tschop M. et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ravinet Trillou C., Delgorge C., Menet C. et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28:640-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Poirier B., Bidouard JP, Cadrouvele C. et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005;7:65-72.[CrossRef][Medline] [Order article via Infotrieve]
• Van Gaal LF, Rissanen AM, Scheen AJ et al. RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pi-Sunyer FX Effect of rimonabant on weight reduction and weight maintenance: RIO North America (RIO-NA) trial. Circulation 2005; 111:1727.

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 2, 58-61 (2006)
DOI: 10.1177/14746514060060020301


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Broom, I. Search for Related Content Social Bookmarking                         What's this?